Dissecting aggressive B-cell lymphoma through genomic analysis - What is clinically relevant?

Area of Science:

• Hematology
• Oncology
• Genomics

Background:

• Aggressive B-cell lymphomas are a heterogeneous group of cancers originating from B lymphocytes.
• Genomic insights are crucial for refining lymphoma classification and identifying therapeutic targets.

Purpose of the Study:

• To summarize the impact of genomic analyses on the classification and understanding of aggressive B-cell lymphomas.
• To highlight the identification of targetable biology through various genomic techniques.

Main Methods:

• Karyotyping to identify chromosomal translocations (e.g., MYC, BCL2, BCL6).
• Gene expression profiling to define molecular subgroups, such as activated B-cell-like and germinal centre B-cell-like in diffuse large B-cell lymphoma (DLBCL).
• Next-generation sequencing to characterize mutational landscapes.

Main Results:

• Key translocations have influenced the World Health Organization classification of lymphomas.
• Distinct molecular subgroups within DLBCL have been identified.
• Genomic profiling reveals mutations in genes related to signaling, epigenetics, differentiation, and immune evasion, with subtype-specific enrichment.
• These mutational signatures offer insights into lymphoma phenotypes and potential therapeutic targets.

Conclusions:

• Genomic analyses are transforming the understanding and classification of aggressive B-cell lymphomas.
• The identification of specific mutations and molecular subgroups provides a foundation for developing targeted therapies.
• Challenges remain in integrating these advanced genomic assays into routine clinical practice.